Sort
4,870 grants matching “glp 1”
Functional characterization of endocrine taste cells
$209,239Robert F Margolskee · Icahn School Of Medicine At Mount Sinai · R01 · FY2009 · DC
A live attenuated vaccine for leishmaniasis
$208,827Abhay R. Satoskar · Ohio State University · R21 · FY2018 · AI
PDZ-targeted Therapeutics for Cervical Cancer
$208,622Michael Paul Belmares · Arbor Vita Corporation · R43 · FY2010 · CA
Thermostable RG1-VLPs, a candidate broadly protective HPV vaccine for the prevention of cervical cancer
$208,552Warner King Huh · Johns Hopkins University · P50 · FY2021 · CA
Elucidating the contributions of c-di-GMP and PlzA to tick- and mammalian host-adaptation in Lyme disease spirochetes
$208,073Melissa J Caimano · University Of Connecticut Sch Of Med/Dnt · R21 · FY2024 · AI
03-DK-0245 (Effect of AC2993 (synthetic exendin-4) on pancreatic islet function)
$207,918James Balow · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK
Theranostic system for targeted, sustained-delivery with quantitative "hot spot" MPI of magnetic extracellular vesicles
$207,607Dian Respati Arifin · Johns Hopkins University · R21 · FY2023 · EB
Sweet taste receptors and glucose metabolism in healthy and T2DM humans
$207,458Karen L Teff · Monell Chemical Senses Center · R21 · FY2011 · DK
Advancing ARP-1536, an Anti-VE-PTP Antibody, as an Adjunctive Therapy for the Treatment of Sight-Threatening Retinopathies
$207,281Kevin G. Peters · Aerpio Therapeutics, Inc. · R44 · FY2019 · EY
Carbon Monoxide Delivery in Sepsis and Acute Lung Injury
$207,166Augustine M Choi · Brigham And Women'S Hospital · P01 · FY2014 · HL
Core D: PREVENT Program Regulatory Affairs Core
$206,892Ian Michael McGowan · University Of Louisville · U19 · FY2016 · AI
Theranostic system for targeted, sustained-delivery with quantitative "hot spot" MPI of magnetic extracellular vesicles
$206,515Dian Respati Arifin · Johns Hopkins University · R21 · FY2022 · EB
Effects of Targeting Immune Activation and Intestinal Barrier on Comorbidities in People with HIV
$206,283Janet Lo · Massachusetts General Hospital · K24 · FY2024 · AI
Neuroeconomics of sugars: Glucose vs. fructose effects on reward signaling
$206,250John R. Monterosso · University Of Southern California · R21 · FY2018 · DA
Effects of Targeting Immune Activation and Intestinal Barrier on Comorbidities in People with HIV
$206,175Janet Lo · Massachusetts General Hospital · K24 · FY2025 · AI
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients
$205,992Frank Sciavolino · Thetis Pharmaceuticals, Llc · R44 · FY2017 · DK
Regulation of germline proliferation and differentiation
$205,972Judith Kimble · University Of Wisconsin-Madison · R01 · FY2007 · GM
Monitoring chemosensory responses of GLP-1 enteroendocrine cells
$205,731Bedrich Mosinger · Icahn School Of Medicine At Mount Sinai · R21 · FY2007 · DK
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
$205,593Craig Patrick Ramirez · Tezcat Laboratories Llc · R44 · FY2025 · CA
Preclinical Development of Flagellin as a Mucosal Adjuvant in Biodefense Vaccines
$205,338Steven B. Mizel · Wake Forest University Health Sciences · U01 · FY2009 · AI
Bioanalytical Core
$204,796Pedro A. Jose · Children'S Research Institute · U54 · FY2015 · HD
Determining the critical time window of action of Parkinson mutant alpha synuclein expression in mice
$204,688Andrew S McCallion · Johns Hopkins University · R21 · FY2025 · NS
Risk Factors and Etiology of Obesity and Type 2 Diabetes
$204,276Jonathan Krakoff · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2013 · DK
Mucus Penetrating Nanoparticles for Small Cell Lung Cancer
$203,247Justin S. Hanes · Johns Hopkins University · U54 · FY2011 · CA
Is there a common allosteric binding site for all GPCRs?
$203,137Zhijun Li · University Of The Sciences Philadelphia · R15 · FY2020 · GM